KBC Securities - BIOTALYS NV (BTLS) Morning Notes : BTLS BB

Report

KBC Securities

Guy Sips ...

Hilde Van Boxstael
Wim Lewi

Morning Notes : BTLS BB

: BTLS BB

24/05/2024 1 EN

Underlying

BIOTALYS NV

See profile

BE0974386188 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Hilde Van Boxstael

Wim Lewi

Other Reports on these Companies

KBC Securities

Biotech State of Affairs in Life Sciences

We provide an extensive overview on our life sciences coverage universe. The note covers recent updates, as well as upcoming catalysts, cash runway and estimates for these companies.

June 12, 2024 June 12, 2024 1 EN

KBC Securities

Biotalys A llama-inspired way to protect crops

Biotalys uses large molecule antibody technology from the pharmaceutical industry to develop innovative crop protection solutions. Its first product, the biofungicide Evoca, is derived from the AGROBODY Foundry platform and targets the high-growth biological crop protection market. Biotalys focuses on cost-effective R&D to introduce new modes of action in fungicides and insecticides, with regulatory processes in the US and EU progressing. It has commercial agreements in place for production and marketing and is managed by an experienced team. Recently, Biotalys transitioned to its second gene...

May 24, 2024 May 24, 2024 1 EN

Ackermans & van Haaren Acquisition Of 33.3% Stake In V.Group

AvH has announced that it has acquired 33.3% of V.Group for an equity investment of $150.0m (€140.0m; excl. acquisition debt financing). In this transaction, AvH teamed up with European investment fund manager ‘STAR Capital' and the transaction is expected to be closed during 2H24. V.Group is a market-leading ship management and marine support service provider to ship owners and operators around the world. V.Group is headquartered in London, United Kingdom. The company has a global presence with 50 offices across 30 countries and employs c. 2.900 employees worldwide. We welcome this news – AvH...

59m 59m 1 EN

Thomas Vranken

Thomas Vranken

argenx 2030 vision announced; PC-POTS discontinued

argenx unveiled its 2030 vision “Taking Breakthrough Science to 50,000 Patients” to be presented in-depth during its upcoming R&D Day on July 16. The presentation will include topline Phase 2 data for efgar in Sjogren's disease and for empa in MMN, as well as additional detail on studies in myositis, DGF, DM, new indications and a next wave of clinical candidates. Development in PC-POTS has also been discontinued as Phase 2 data revealed no improvement vs. placebo. We scrap PC-POTS from our SOTP, now landing at a TP of € 420 (previously € 435), while we reiterate a Buy rating and look forward ...

1h / 1m 1h / 1m 1 EN

Jacob Mekhael

Jacob Mekhael

Autolus FIRST LOOK: Presents additional obe-cel analysis in r/r ALL at EHA

Autolus presented additional analysis for obe-cel in r/r adult ALL at the European Hematology Association (EHA) congress, which included previously presented durability data for obe-cel showing that 40% of patients were in ongoing remission without subsequent therapies at 21.5 months follow up. The new presentations included i) the impact of inotuzumab (INO)-containing bridging therapy on treatment outcomes, and ii) droplet digital PCR and flow cytometry sensitivity for measuring CAR T-cell kinetics. We reiterate our $11 TP and BUY rating.

1h / 1m 1h / 1m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : BTLS BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Biotech State of Affairs in Life Sciences

Biotalys A llama-inspired way to protect crops

Ackermans & van Haaren Acquisition Of 33.3% Stake In V.Group

argenx 2030 vision announced; PC-POTS discontinued

Autolus FIRST LOOK: Presents additional obe-cel analysis in r/r ALL at EHA

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe